Cabozantinib Market

Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc.

Cabozantinib Market contains market size and forecasts of Cabozantinib in global, including the following market information:

• Global Cabozantinib Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Cabozantinib Market Sales, 2017-2022, 2023-2028, (Tons)
• Global top five Cabozantinib companies in 2021 (%)

The global Cabozantinib market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Capsule Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cabozantinib include Exelixis, Tecoland Corporation, Fermion Oy, Sun Pharmaceutical Industries Limit, MSN Laboratories Pvt Ltd, Shanghai Hope Chem, Hetero Drugs Limited, Huateng Pharmaceutical Co. and Bio Nova Pharmaceuticals Private Limited and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Cabozantinib manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cabozantinib Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Tons)

Global Cabozantinib Market Segment Percentages, by Type, 2021 (%)

• Capsule
• Tablet

Global Cabozantinib Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Tons)

Global Cabozantinib Market Segment Percentages, by Application, 2021 (%)

• Medullary Thyroid Cancer Treatment
• Second Line Treatment for Renal Cell Carcinoma

Global Cabozantinib Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Tons)

Global Cabozantinib Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Cabozantinib revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Cabozantinib revenues share in global market, 2021 (%)
• Key companies Cabozantinib sales in global market, 2017-2022 (Estimated), (Tons)
• Key companies Cabozantinib sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Exelixis
• Tecoland Corporation
• Fermion Oy
• Sun Pharmaceutical Industries Limit
• MSN Laboratories Pvt Ltd
• Shanghai Hope Chem
• Hetero Drugs Limited
• Huateng Pharmaceutical Co.
• Bio Nova Pharmaceuticals Private Limited
• AlchemyPharm